MedPath

A human study for investigating effects of Acanthopanax koreanum Nakai extract consumption on hepatic function in moderate drinkers

Not Applicable
Completed
Conditions
Diseases of the digestive system
Registration Number
KCT0001353
Lead Sponsor
Jeju Technopark
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
All
Target Recruitment
69
Inclusion Criteria

1) Wiling to provide own written informed consent to trial participation
2) Adult male & female = 20 years
3) Moderate drinkers
- Male: = 210g of alcohol/week
- Female: = 140g of alcohol/week
4) gamma-Glutamyl Transpeptidase(GGT) = 60 IU/L
5) Proven fatty liver (liver ultrasound)

Exclusion Criteria

1) More than or equal to 420 g of alcohol/week
2) Serum alanine Transaminase, aspartate Transaminase or total bilirubin > 5 x upper normal limit
3) Following past medical history
? Viral hepatitis (HBsAg+, HCV-Ab+), liver failure, primary biliary cirrhosis, drug-induced liver disease, biliary disease, autoimmune liver disease, surgery-induced liver disease, hereditary liver disease
? Systemic inflammation(tuberculosis), severe cardiovascular, digestive, renal, thyroid disease, autoimmune disease, malignant neoplasm, multisystem failure, inflammatory bowel disease, psychiatric disease, HIV positive, uncontrolled hypertension
4) Organ or bone marrow transplant recipient
5) Gastro-intestinal surgery (except appendectomy)
6) Concomittent medications
? Anti-tuberculosis, Non-steroidal anti-Inflammatory drugs, antibiotics: isoniazid, rifampin etc.
? Cholagogues: choline orotate, chenodeoxycholic acid, ursodeoxycholic acid etc.
? Liver pills: biphenyl-dimethyl-dicarboxylate, ornithine HCL, silymarin, carnitine orotate, citiolone, arginine thiazolidine carboxylate, coriolan, urazamide, ornithine arspartate, arginine tidiacicate, metadoxine, silybin, malotilate, timonacic etc.
? Hepatotoxic drugs: acetaminophen, amoxicillin, amiodarone, chlorpromazine, ciprofloxacin, diclofenac, erythromycin, fluconazole, methyldopa, oral contraceptives, phenytoin, rifampin etc.
? Anti-epileptics: cytochrom P450 inducer, phenobarbital etc.
7) Continuous consumption of health functional foods (antioxydant vitamin, Oriental Raisin Tree, Anthocyanin, Lentinula edodes, Milk Thistle) within 8 weeks prior to first visit
8) Continuous consumption herbal medicines
9) Hypersensitivity to Acanthopanax koreanum Nakai extract
10) Participation of other clinical study within 12 weeks prior to first visit
11) Pregnant, lactating, child-bearing age women
12) Ineligible for study participation due to other reasons, according to the investigator’s judgment

Study & Design

Study Type
Interventional Study
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
gamma-Glutamyl Transpeptidase(GGT);Adverse events
Secondary Outcome Measures
NameTimeMethod
Alanine Transaminase;Aspartate Transaminase;Lactate Dehydrogenase;Hepatic fat level (Liver-CT)
© Copyright 2025. All Rights Reserved by MedPath